CN1842328A - 可用作抗炎剂的α－氨基酰胺衍生物 - Google Patents

可用作抗炎剂的α－氨基酰胺衍生物 Download PDF

Info

Publication number
CN1842328A
CN1842328A CNA2004800242753A CN200480024275A CN1842328A CN 1842328 A CN1842328 A CN 1842328A CN A2004800242753 A CNA2004800242753 A CN A2004800242753A CN 200480024275 A CN200480024275 A CN 200480024275A CN 1842328 A CN1842328 A CN 1842328A
Authority
CN
China
Prior art keywords
benzylamino
propionamide
fluorobenzyloxy
methyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800242753A
Other languages
English (en)
Chinese (zh)
Inventor
P·萨尔瓦蒂
O·韦内罗尼
E·巴尔班蒂
F·鲁杰罗
L·贝纳蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Newron Pharmaceuticals SpA
Original Assignee
Newron Pharmaceuticals SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharmaceuticals SpA filed Critical Newron Pharmaceuticals SpA
Publication of CN1842328A publication Critical patent/CN1842328A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2004800242753A 2003-08-25 2004-04-22 可用作抗炎剂的α－氨基酰胺衍生物 Pending CN1842328A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49772203P 2003-08-25 2003-08-25
US60/497,722 2003-08-25

Publications (1)

Publication Number Publication Date
CN1842328A true CN1842328A (zh) 2006-10-04

Family

ID=34216147

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800242753A Pending CN1842328A (zh) 2003-08-25 2004-04-22 可用作抗炎剂的α－氨基酰胺衍生物

Country Status (21)

Country Link
US (2) US20070276046A1 (cg-RX-API-DMAC7.html)
EP (1) EP1658062B1 (cg-RX-API-DMAC7.html)
JP (1) JP5042625B2 (cg-RX-API-DMAC7.html)
KR (1) KR101233711B1 (cg-RX-API-DMAC7.html)
CN (1) CN1842328A (cg-RX-API-DMAC7.html)
AT (1) ATE457724T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004266494B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0413982A (cg-RX-API-DMAC7.html)
CA (1) CA2536764C (cg-RX-API-DMAC7.html)
CY (1) CY1109992T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004025586D1 (cg-RX-API-DMAC7.html)
DK (1) DK1658062T3 (cg-RX-API-DMAC7.html)
ES (1) ES2339021T3 (cg-RX-API-DMAC7.html)
IL (1) IL173886A (cg-RX-API-DMAC7.html)
NO (1) NO335245B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ545502A (cg-RX-API-DMAC7.html)
PL (1) PL1658062T3 (cg-RX-API-DMAC7.html)
PT (1) PT1658062E (cg-RX-API-DMAC7.html)
RU (1) RU2396251C2 (cg-RX-API-DMAC7.html)
SI (1) SI1658062T1 (cg-RX-API-DMAC7.html)
WO (1) WO2005018627A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101687773B (zh) * 2007-06-15 2014-07-30 纽朗制药有限公司 取代的2-[2-(苯基)乙氨基]烷酰胺衍生物及其作为钠和/或钙通道调节剂的应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018627A1 (en) * 2003-08-25 2005-03-03 Newron Pharmaceuticals, Spa Alpha-aminoamide derivatives useful as anti-inflammatory agents
EP1557166A1 (en) 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
AU2005282028B2 (en) * 2004-09-10 2011-03-24 Newron Pharmaceuticals S.P.A. (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators
DK1963280T3 (en) * 2005-12-22 2015-12-14 Newron Pharm Spa 2-phenylethylamine derivatives by calcium and / or sodium channel
HUE030233T2 (en) 2006-06-19 2017-04-28 Newron Pharm Spa High purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as medicaments and pharmaceutical compositions containing them
CA2706789C (en) 2007-12-11 2016-09-06 Newron Pharmaceuticals S.P.A. Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree
CA2794389C (en) 2010-04-27 2016-08-23 Newron Pharmaceuticals S.P.A. Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
RU2449805C1 (ru) 2011-01-27 2012-05-10 Общество С Ограниченной Ответственностью "Гармония" Пептидная фармацевтическая композиция, средство на ее основе для лечения гастродуоденальных заболеваний, вызываемых helicobacter pylori, и способ его использования
DE102012108965B4 (de) 2012-09-24 2014-08-14 Exscitron Gmbh Stromquelle mit verbesserter Dimmvorrichtung

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9726987D0 (en) * 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
GB9727523D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
SE9801494D0 (sv) * 1998-04-28 1998-04-28 Astra Pharma Prod Novel use
RU2164512C1 (ru) * 1999-07-27 2001-03-27 Всероссийский научный центр по безопасности биологически активных веществ Производные аминокислот, проявляющие антиаритмическую активность
GB9930079D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
DE60127410T2 (de) * 2000-07-27 2007-12-13 Pharmacia Corp. Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen
ES2253579T3 (es) * 2001-09-03 2006-06-01 Newron Pharmaceuticals S.P.A. Composicion farmaceutica que comprende gabapentina o un analogo suyo y una alfa-aminoamida y su uso analgesico.
US6897319B2 (en) * 2001-12-27 2005-05-24 Ortho-Mcneil Pharmaceutical, Inc. Useful aroyl pyrrole heteroaryl methanones and methanols
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
AU2004207010A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
WO2004066987A2 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
WO2005018627A1 (en) * 2003-08-25 2005-03-03 Newron Pharmaceuticals, Spa Alpha-aminoamide derivatives useful as anti-inflammatory agents
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
AU2005282028B2 (en) * 2004-09-10 2011-03-24 Newron Pharmaceuticals S.P.A. (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators
DK1963280T3 (en) * 2005-12-22 2015-12-14 Newron Pharm Spa 2-phenylethylamine derivatives by calcium and / or sodium channel
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
HUE030233T2 (en) * 2006-06-19 2017-04-28 Newron Pharm Spa High purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as medicaments and pharmaceutical compositions containing them
WO2008151702A1 (en) * 2007-06-15 2008-12-18 Newron Pharmaceuticals S.P.A. Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
CA2706789C (en) * 2007-12-11 2016-09-06 Newron Pharmaceuticals S.P.A. Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree
NZ586182A (en) * 2007-12-19 2012-02-24 Newron Pharm Spa Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101687773B (zh) * 2007-06-15 2014-07-30 纽朗制药有限公司 取代的2-[2-(苯基)乙氨基]烷酰胺衍生物及其作为钠和/或钙通道调节剂的应用

Also Published As

Publication number Publication date
NZ545502A (en) 2010-04-30
EP1658062A1 (en) 2006-05-24
IL173886A (en) 2012-09-24
AU2004266494A1 (en) 2005-03-03
ES2339021T3 (es) 2010-05-14
SI1658062T1 (sl) 2010-05-31
AU2004266494B2 (en) 2010-04-08
CA2536764A1 (en) 2005-03-03
DK1658062T3 (da) 2010-05-31
KR101233711B1 (ko) 2013-02-18
WO2005018627A8 (en) 2005-09-01
EP1658062B1 (en) 2010-02-17
RU2006105634A (ru) 2006-08-10
KR20060128825A (ko) 2006-12-14
WO2005018627A1 (en) 2005-03-03
JP2007503424A (ja) 2007-02-22
PT1658062E (pt) 2010-03-31
BRPI0413982A (pt) 2006-11-07
RU2396251C2 (ru) 2010-08-10
JP5042625B2 (ja) 2012-10-03
ATE457724T1 (de) 2010-03-15
US20100016440A1 (en) 2010-01-21
US20070276046A1 (en) 2007-11-29
CY1109992T1 (el) 2014-09-10
NO20060896L (no) 2006-03-09
NO335245B1 (no) 2014-10-27
PL1658062T3 (pl) 2010-07-30
DE602004025586D1 (de) 2010-04-01
CA2536764C (en) 2013-09-17
IL173886A0 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
US20100016440A1 (en) Alpha-aminoamide derivatives useful as anti-inflammatory agents
HK1040058A1 (zh) 光学纯度(+)-降西沙必利对治疗呼吸暂停、贪食症和其它疾病的用途
CN1192199A (zh) 2－(4－取代)－苄基氨基－2－甲基－丙酰胺衍生物
US20220096444A1 (en) Prophylactic or therapeutic agent for delirium
JP2007518763A (ja) 下部尿路障害の処置に有用なα−アミノアミド誘導体
CN1159305C (zh) 新的2-(n-氰基亚氨基)噻唑烷-4-酮衍生物
CN1738611A (zh) 用作抗偏头痛剂的α－氨基酰胺衍生物
CN1320036A (zh) 治疗胃－食管返流性疾病的方法和组合物
CN101076328A (zh) 用于睡眠障碍的预防或治疗剂
HK1040059A1 (zh) 光学纯度(-)-降西沙必利对治疗呼吸暂停、贪食症和其它疾病的用途
CN1859846A (zh) 白屈菜赤碱、其类似物及其在治疗躁郁症和其他认知紊乱中的应用
CN1592615A (zh) 含有二甲双胍和4－氧代丁酸的药物组合物及其在治疗糖尿病中的用途
HK1093022A (en) Alpha-aminoamide derivatives useful as anti-inflammatory agents
CN1382045A (zh) 20－羟基二十碳四烯酸合成酶抑制剂
CN1633304A (zh) 含有α－葡糖苷酶抑制剂和4－氧代丁酸的药物组合物以及它们治疗糖尿病的用途
KR20130094811A (ko) 류코트리엔 관련 병증 치료용 페닐알킬 ｎ-히드록시우레아
CN1946712A (zh) 吡咯烷衍生物
CN1929830A (zh) Nmda受体拮抗剂联合抗癫痫药物治疗癫痫症和其他中枢神经系统疾病的组合物和方法
MXPA06002189A (en) Alpha-aminoamide derivatives useful as anti-inflammatory agents
CN101648891B (zh) 芳基环丁基化合物及其在制备减肥药物中的应用
CN1784223A (zh) 苯氧基乙酸用于治疗机能亢进性膀胱
CN1791397A (zh) 包括莫达芬尼和不同药物的药物组合
HK40000275A (en) Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium
CN1913881A (zh) 慢性脑循环不全症的预防和/或治疗剂
CN1599604A (zh) 4－氧代丁酸衍生物在治疗炎症中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1093022

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20061004

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1093022

Country of ref document: HK